Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-short-term high-dose EPO regimen for perioperative anemia in primary THA/TKA
ChiCTR2500104525Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of epoetin alfa in anemia, hip osteoarthritis and disorders of knee (4 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Hemoglobin level, Blood loss volume and 2 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
epoetin alfa
03
Conditions
anemiahip osteoarthritisdisorders of knee
Beyond the preview
Go deeper on ChiCTR2500104525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104525.